TaILOR试验:患者发起随访策略与标准路径在炎症性关节炎中的临床与成本效果比较研究方案
TaILOR是一项在英国32家二级保健NHS站点开展的两臂、实用性、平行组、优效性随机对照试验,计划纳入438例稳定期炎症性关节炎患者,1:1随机分配至患者发起随访(PIFU,含固定24个月安全网预约)或标准随访(每6-12个月复诊)。主要结局为24个月时肌肉骨骼生活质量,同时评估成本效果、疾病活动、 flares、患者信心等,并嵌入定性研究。
要点
- PIFU组设固定24个月安全网预约,标准组每6-12个月复诊。
- 主要结局为24个月时肌肉骨骼生活质量,采用优效性设计。
- 研究同时评估增量成本、成本效果、治疗升级、疾病活动、flares及患者信心。
核心结论
- 该研究旨在为炎症性关节炎患者发起随访(PIFU)策略提供与标准路径比较的确定性评估,覆盖临床效果、成本效果、安全性和可接受性。
研究设计与样本
- 两臂、实用性、平行组、优效性随机对照试验,嵌入定性研究,在英国32家二级保健NHS站点开展。
- 计划随机438例18岁及以上、诊断至少2年、病情稳定的炎症性关节炎患者,按1:1分配至PIFU组(含固定24个月安全网预约)或标准组(每6-12个月随访)。
- 纳入标准包括基于NHS England指南和常规治疗团队判断适合PIFU;试验包含内部招募可行性试点、卫生经济学和定性分析。
主要发现
- 原文未报告研究结果;主要结局为24个月时肌肉骨骼生活质量,用于评估PIFU相对标准随访的有效性。
- 次要结局包括生活质量、增量成本、成本效果、治疗升级、疾病活动、 flares、患者与临床团队互动的信心(患者感知的医患互动效能)、抑郁及PIFU可接受性(通过定性访谈)。
关键数值与推荐
- PIFU组设固定24个月安全网预约;标准组每6-12个月随访一次。
- 纳入标准:年龄≥18岁、诊断炎症性关节炎至少2年、病情稳定、基于NHS England指南和常规治疗团队判断适合PIFU。
临床怎么用
- 该研究将为炎症性关节炎患者选择PIFU路径提供效果、安全性、成本效果和可接受性证据,帮助优化服务配置和患者筛选。
局限性
- 原文未报告研究结果;作为研究方案,尚无PIFU与标准随访比较的疗效和安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory arthritis comprises lifelong conditions, such as rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis that require long-term treatment and regular monitoring. People with inflammatory arthritis usually require long-term treatment with immune-suppressing medications and are typically reviewed in outpatient clinics every 6-12 months, accounting for 1.3 million appointments/year in the UK. The National Health Service (NHS) is implementing a move to patient-initiated follow-up (PIFU) where patients request appointments as required. To date, there are small studies of PIFU in rheumatoid arthritis and none in other arthritis. Research is required to configure services to optimise outcomes, inform patients and clinicians of the effectiveness and safety of PIFU and ensure that suitable patients are selected for this pathway. METHODS: TaILOR is a two-arm, pragmatic, parallel group, superiority, randomised controlled clinical study, with an embedded qualitative study conducted across 32 secondary care NHS sites in the UK. Eligible participants must be 18 years or older, with stable inflammatory arthritis, and diagnosed for at least 2 years. In addition, they need to be suitable for PIFU based on NHS England guidance and in the opinion of their usual care team; 438 participants will be randomised in a 1:1 ratio to either PIFU, with a fixed 24-month safety net appointment, or standard care, with 6-12 monthly follow-up visits. The trial includes an internal recruitment feasibility pilot, as well as health economics and qualitative analyses. The primary outcome will assess the effectiveness of PIFU compared to standard care on musculoskeletal quality of life at 24 months. Secondary outcomes include quality of life, incremental costs, cost-effectiveness, treatment escalation, disease activity, flares, patient confidence in interactions with their clinical team (patient perceived efficacy in patient-physician interactions), depression and acceptability of PIFU (via qualitative interviews). DISCUSSION: As a national multi-centre study, this will provide the definitive evaluation of PIFU for inflammatory arthritis. Qualitative analysis will generate insights into individual and contextual factors affecting the acceptability of PIFU, identify variation across sites or between patients and provide information on how this can be addressed. TRIAL REGISTRATION: ISRCTN ISRCN10480648. Registered on 17 January 2025. Protocol version {2}: Version 3.0 date 04 Dec 2025.
引用
- Brewer G, Harris V, Mwema C, et al. TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol. Trials. 2026. PMID: 42400057. doi:10.1186/s13063-026-09868-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。